Head to Head Analysis: Amicus Therapeutics (FOLD) vs. Pernix Therapeutics (PTX)

Amicus Therapeutics (NASDAQ: FOLD) and Pernix Therapeutics (NASDAQ:PTX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Earnings and Valuation

This table compares Amicus Therapeutics and Pernix Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amicus Therapeutics $4.96 million 498.81 -$200.04 million ($1.83) -8.13
Pernix Therapeutics $140.86 million 0.19 -$169.59 million ($14.78) -0.16

Pernix Therapeutics has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Pernix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

16.4% of Pernix Therapeutics shares are owned by institutional investors. 3.4% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 1.4% of Pernix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Amicus Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Pernix Therapeutics has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.

Profitability

This table compares Amicus Therapeutics and Pernix Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amicus Therapeutics -1,092.37% -63.54% -23.46%
Pernix Therapeutics -97.10% N/A -37.13%

Analyst Ratings

This is a breakdown of recent ratings for Amicus Therapeutics and Pernix Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amicus Therapeutics 0 1 6 0 2.86
Pernix Therapeutics 0 0 0 0 N/A

Amicus Therapeutics currently has a consensus price target of $19.50, suggesting a potential upside of 31.05%. Given Amicus Therapeutics’ higher possible upside, research analysts plainly believe Amicus Therapeutics is more favorable than Pernix Therapeutics.

Summary

Pernix Therapeutics beats Amicus Therapeutics on 7 of the 13 factors compared between the two stocks.

About Amicus Therapeutics

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

About Pernix Therapeutics

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit